Hayek Kallen Investment Management increased its position in Pfizer Inc. (NYSE:PFE) by 1.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 98,437 shares of the biopharmaceutical company’s stock after buying an additional 1,179 shares during the quarter. Pfizer accounts for 2.2% of Hayek Kallen Investment Management’s portfolio, making the stock its 18th largest position. Hayek Kallen Investment Management’s holdings in Pfizer were worth $3,537,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. 1 North Wealth Services LLC purchased a new position in shares of Pfizer during the third quarter valued at approximately $29,000. Bourgeon Capital Management LLC purchased a new stake in Pfizer during the third quarter valued at $32,000. Evolution Wealth Advisors LLC purchased a new stake in Pfizer during the second quarter valued at $34,000. IMA Wealth Inc. increased its position in Pfizer by 144.5% during the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 477 shares during the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management purchased a new stake in Pfizer during the third quarter valued at $36,000. Institutional investors own 71.52% of the company’s stock.

PFE traded up $0.14 during midday trading on Friday, reaching $37.05. The company had a trading volume of 24,924,227 shares, compared to its average volume of 23,366,957. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. The business has a 50-day moving average of $36.62 and a two-hundred day moving average of $39.26. The company has a market cap of $207.30 billion, a P/E ratio of 12.35, a P/E/G ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. The firm had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $12.37 billion. During the same quarter last year, the business posted $0.78 earnings per share. The firm’s revenue was down 4.6% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 3.89%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio is currently 48.00%.

In other Pfizer news, Director Scott Gottlieb bought 3,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the transaction, the director now owns 3,000 shares of the company’s stock, valued at approximately $104,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

A number of analysts have commented on the company. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research report on Tuesday, October 1st. ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Bank of America assumed coverage on Pfizer in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target for the company. DZ Bank upgraded Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a research report on Wednesday, August 28th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Nine analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $44.02.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Stocks Increasing Dividends

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.